The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Beau Ances MD & Tammie Benzinger MD
Project Title: F 18 T807 Tau PET Imaging of Older (≥ 50 years old) HIV Infected (HIV+) and HIV Uninfected (HIV-) Individuals (IND 123119, Protocol G)
Date: December 21, 2021 at 5:18 pm
Request ID: D1807
Aim 1: Perform human in vivo tau imaging using F 18 T807 in 30 older (≥ 50 years old) HIV+ participants and 30 HIV- controls. All 60 participants will have neuroimaging, neuropsychological performance testing, and a clinical examination at a visit.
Aim 2: Compare tau deposition in HIV+ individuals compared to HIV- individuals.
Aim 3: Correlate regional quantitative T807 binding potentials (BPs) with cognitive impairment, as documented by neuropsychological performance tests, in HIV+ and HIV- individuals.
Aim 4:
Investigator: Karin Meeker
Project Title: The Relationship Between Functional Brain Networks and Cognitive Intraindividual Variability in Healthy Aging and Early Alzheimer Disease
Date: December 21, 2021 at 5:18 pm
Request ID: D1816
Aim 1: Assess magnitude of DAN- DMN anticorrelations at rest in relation to IIV across cognitive domains in healthy individuals, as well as those with early AD.
Aim 2: Repeat and compare analysis to previous ADNI study
Aim 3:
Aim 4:
Investigator: Tan Lan; Yu Jin-tai
Project Title: A potential endophenotype for Alzheimer�s disease: cerebrospinal fluid progranulin
Date: December 21, 2021 at 5:18 pm
Request ID: D1815
Aim 1: To reveal novel variants associated with progranulin (PGRN) levels
Aim 2: To explore the roles of associated-variants in AD
Aim 3: To look at potential biological, cellular, and molecular categories that may be associated with PGRN levels
Aim 4: To validate the assocition results in different datasets
Investigator: Ellen Grober
Project Title: Stage of Objective Memory Impairment (SOMI) Before Death Predicts Neuropathology in Preclinical Alzheimer�s Disease
Date: December 21, 2021 at 5:18 pm
Request ID: D1814
Aim 1: To explore the relationship between free recall (FR), total recall (TR) and the SOMI system and the “ABC” score indicating likelihood of AD pathologic change.
Aim 2: To explore the relationship between the memory measures and quantitative measures of regional pathology including NFT�s and NPs from available brain regions.��
Aim 3:
Aim 4:
Investigator: Catherine Roe
Project Title: Assessing Differences in Novel Predictors of Objective Driving Exposure among Older Adults
Date: December 21, 2021 at 5:18 pm
Request ID: D1813
Aim 1: To assess the extent to which psychometric scores, biomarkers, cognition, self-reported driving, and driving performance play a role in driving exposure and driving self-regulation.
Aim 2:
Aim 3:
Aim 4:
Investigator: Paul Crane
Project Title: Genome-wide genetic analyses of cognitively-defined AD subgroups
Date: December 21, 2021 at 5:18 pm
Request ID: D1812
Aim 1: Co-calibrate cognitive data for memory, executive functioning, language, and visuospatial functioning
Aim 2: Use those scores to assign people with Alzheimer Clinical Syndrome into cognitively defined subgroups
Aim 3: Perform genome-wide genetic analyses of cognitively defined subgroups compared with cognitively normal elderly controls
Aim 4:
Investigator: GS Day
Project Title: Identifying Factors that Influence Participation in MAP CSF Biomarker Studies
Date: December 21, 2021 at 5:18 pm
Request ID: D1811
Aim 1: Identify participant-specific factors that influence participation in CSF biomarker studies in MAP participants.
Aim 2: Identify procedural factors that influence participation in CSF biomarker studies in MAP participants.
Aim 3:
Aim 4:
Investigator: None
Project Title: Impact of Race in Reported Memory Problem
Date: December 21, 2021 at 5:18 pm
Request ID: D1810
Aim 1: The primary aim is to determine whether the self-reported versus informant-reported memory problems in African American and Non-Hispanic White non-demented and very mildly of mildly demented Alzheimer disease (AD) individuals correlate with cognitive performance and progression of cognitive dysfunct
Aim 2: Secondary aim includes determining if there is any correlation or racial difference in self-reported and informant reported memory problems and psychometric testing.
Aim 3:
Aim 4:
Investigator: Anne Fagan
Project Title: Evaluation of alpha-synuclein in CSF of MAP participants who have come to autopsy
Date: December 21, 2021 at 5:18 pm
Request ID: D1809
Aim 1: evaluate the potential utility of measures of CSF aSN as a marker of underlying LB pathology in LOAD
Aim 2:
Aim 3:
Aim 4:
Investigator: Lindsay Farrer; Gyungah Jun
Project Title: Genomic and Biological Studies of APOE e2 in Alzheimer�s Disease
Date: December 21, 2021 at 5:18 pm
Request ID: D1808
Aim 1: Conduct an AD GWAS among APOE ɛ2 carriers using HRC-imputed ADGC datasets to confirm preliminary association findings and identify new loci, and replicate top findings in independent samples.
Aim 2: Validate and identify new functional variants for AD-associated loci using whole exome and whole genome sequence data.
Aim 3: Perform pathway analyses to elucidate pathways and mechanisms linking genes to disease.
Aim 4: